TY - JOUR
T1 - FAPI-PET in Cardiovascular Disease
AU - Higuchi, Takahiro
AU - Serfling, Sebastian E.
AU - Leistner, David M.
AU - Speer, Thimoteus
AU - Werner, Rudolf A.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024
Y1 - 2024
N2 - PET probes targeting fibroblasts are frequently used for varying applications in oncology. In recent years, the clinical spectrum has been expanded towards cardiovascular medicine, e.g., after myocardial infarction, in aortic stenosis or as a non-invasive read-out of atherosclerosis. We herein provide a brief overview of the current status of this PET radiotracer in the context of cardiovascular disease, including translational and clinical evidence. In addition, we will also briefly discuss future applications, e.g., the use of fibroblast-targeting PET to investigate bilateral organ function along the cardiorenal axis.
AB - PET probes targeting fibroblasts are frequently used for varying applications in oncology. In recent years, the clinical spectrum has been expanded towards cardiovascular medicine, e.g., after myocardial infarction, in aortic stenosis or as a non-invasive read-out of atherosclerosis. We herein provide a brief overview of the current status of this PET radiotracer in the context of cardiovascular disease, including translational and clinical evidence. In addition, we will also briefly discuss future applications, e.g., the use of fibroblast-targeting PET to investigate bilateral organ function along the cardiorenal axis.
UR - http://www.scopus.com/inward/record.url?scp=85188419431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85188419431&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2024.02.006
DO - 10.1053/j.semnuclmed.2024.02.006
M3 - Review article
C2 - 38519308
AN - SCOPUS:85188419431
SN - 0001-2998
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
ER -
